The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged 8 to 17 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results